OR27-5 The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence

por Yin, Ngwe, Pak, Youngju, Sherman, Steven, Gianoukakis, Andrew, Group, NTCTCS
Publicado 2019

Prolonged duration of response in lenvatinib responders with thyroid cancer

por Gianoukakis, Andrew G, Dutcus, Corina E, Batty, Nicolas, Guo, Matthew, Baig, Mahadi
Publicado 2018

THU265 A U-Shaped Relationship Between Undiagnosed Diabetes And Thyroid Function

por Zafar Alvi, Zara, Karnchanasorn, Rudruidee, Ou, Horng-Yih, Chuang, Lee-Ming, George Gianoukakis, Andrew, Chiu, Ken C
Publicado 2023

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

por Gianoukakis, Andrew G, Flores, Natalia M, Pelletier, Corey L, Forsythe, Anna, Wolfe, Gregory R, Taylor, Matthew H
Publicado 2016

Ultrasensitive Detection of BRAF Mutations in Circulating Tumor DNA of Patients With Metastatic Thyroid Cancer

por Gouda, Mohamed A, Ong, Emily, Huang, Helen J, McPhaul, Laron, Yoon, Steve, Janku, Filip, Gianoukakis, Andrew G
Publicado 2021

SAT-039 The Short-Term Effect of Multiple Kinase Inhibitor (Lenvatinib) on Spermatogenesis in Mice

por Lue, Yanhe, Gianoukakis, Andrew G, Fueger, Patrick T, Teramoto, Darren, Irimia-Domingues, Jose, Bloom-Saldana, Elizabeth, Wang, Christina C L, Swerdloff, Ronald S
Publicado 2020

Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer

por Sipos, Jennifer A, Aloi, Joseph, Gianoukakis, Andrew, Lee, Stephanie L, Klopper, Joshua P, Kung, Jacqueline T, Lupo, Mark A, Morgenstern, David, Prat-Knoll, Cristina, Schuetzenmeister, Andre, Goldner, Whitney S
Publicado 2023

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes

por Haddad, Robert I., Schlumberger, Martin, Wirth, Lori J., Sherman, Eric J., Shah, Manisha H., Robinson, Bruce, Dutcus, Corina E., Teng, Angela, Gianoukakis, Andrew G., Sherman, Steven I.
Publicado 2017

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

por Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Publicado 2021

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 m...

por Taylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran, Brose, Marcia S.
Publicado 2022